The price of X4 Pharmaceuticals Inc (NASDAQ:XFOR) shares last traded on Wall Street rose 12.96% to $0.76.
XFOR stock price is now 54.94% away from the 50-day moving average and -5.93% away from the 200-day moving average. The market capitalization of the company currently stands at $129.74M.
With the price target reduced from $3 to $1, B. Riley Securities Downgraded its rating from Buy to Neutral for X4 Pharmaceuticals Inc (NASDAQ: XFOR). , while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Ragan Paula, President and CEO sold 31,897 shares of the company’s stock on Nov 15 ’24. The stock was sold for $12,583 at an average price of $0.39. Upon completion of the transaction, the President and CEO now directly owns 993,919 shares in the company, valued at $0.76 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 15 ’24, Officer Ragan Paula bought 31,897 shares of the business’s stock. A total of $13,078 was incurred on buying the stock at an average price of $0.41. A total of 30.90% of the company’s stock is owned by insiders.
During the past 12 months, X4 Pharmaceuticals Inc has had a low of $0.26 and a high of $1.60. As of last week, the company has a debt-to-equity ratio of 1.31, a current ratio of 4.89, and a quick ratio of 4.80. The fifty day moving average price for XFOR is $0.48848 and a two-hundred day moving average price translates $0.80986 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc (NASDAQ: XFOR) was released for 2024-06-30. The net profit margin was -1492.34% and return on equity was -26.35% for XFOR.
